Supernus Pharmaceuticals, Inc. (SUPN): financial analysis & fundamentals
Health Care · price $44.19 · market cap —
In short — Supernus Pharmaceuticals, Inc. trades at —× earnings (P/E), —× expected earnings, for a PEG of — and a net margin of —. Revenue growth —. Quick verdict: valuation to review.
Is Supernus Pharmaceuticals, Inc. stock expensive?
Supernus Pharmaceuticals, Inc. has a P/E of — (forward P/E —) and a PEG of —. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: valuation to review.
What is Supernus Pharmaceuticals, Inc.'s net margin?
Supernus Pharmaceuticals, Inc.'s net margin is about — — the share of revenue that ends up as net profit.
What is Supernus Pharmaceuticals, Inc.'s revenue?
Supernus Pharmaceuticals, Inc.'s income statement is detailed on this page.
What is Supernus Pharmaceuticals, Inc.'s market cap?
Supernus Pharmaceuticals, Inc. (SUPN) has a market cap of about —.
Does Supernus Pharmaceuticals, Inc. pay a dividend?
No, Supernus Pharmaceuticals, Inc. does not currently pay a dividend (it reinvests earnings).
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
💬 AI assistant: ask anything about any stock, with the numbers